Compliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals has submitted a routine compliance certificate to BSE for the quarter ended 30 September 2025 under SEBI's Depository Regulations. The certificate, based on confirmation from their Registrar and Transfer Agent Aarthi Consultants Pvt Ltd, confirms that all share certificates received for dematerialization during July–September 2025 were mutilated, cancelled, and the depository's name was substituted as the registered owner within the stipulated 15-day timeline. The filing also confirms that the dematerialized securities remain listed on BSE where the original shares were listed. The document was signed by Executive Director Dhananjaya Alli on 14 October 2025.
This is a routine procedural filing with no material impact on shareholders or the stock price. It simply confirms that share dematerialization activities during the quarter were processed correctly and on time.